HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: A global developer, manufacturer, and marketer of specialized apparatus and scientific instruments for life science research (ADMET screening and molecular biology). The company operates primarily through its "Apparatus and Instrumentation" continuing operations. The "Capital Equipment" segment has been classified as discontinued operations since 2005, with partial divestiture completed in late 2007.

Key Financial Metrics

Note: Net Loss includes a $9.0 million loss from discontinued operations (including a $3.1 million loss on sale of assets). Income from continuing operations was profitable.

Material Changes vs. Prior Period

• Revenue Growth: Driven by the acquisition of Panlab s.l. (October 2007, contributing $2.9 million in Q4), increased sales from the Anthos product line ($1.5 million increase), and favorable foreign exchange rates (+$3.0 million).
• Margin Compression: Gross margin decreased to 48.3% from 50.0% due to the lower-margin product mix of the newly acquired Panlab subsidiary and increased sales of lower-margin Anthos products.
• Debt Increase: Total debt rose to $7.7 million from $3.0 million, primarily due to a $5.0 million draw on the credit facility to fund the Panlab acquisition and the assumption of $2.3 million in notes payable.
• Discontinued Operations: Completed the sale of Genomic Solutions Division and Maia Scientific in November 2007 for $1.0 million cash plus earn-out, recording a $3.1 million loss on disposition. The COPAS flow cytometry line remains in discontinued operations pending separate sale.

Guidance, Outlook, and Risks

Management Initiatives for 2008:

• Launch of a new major Harvard Apparatus catalog (February 2008).
• Expansion of Panlab products into US markets.
• Signing of a new distribution contract with GE Healthcare (current agreement terminates September 2008).
• Launch of new 2-D electrophoresis products.
• Consolidation of business functions to reduce operating expenses.

Key Risks and Contingencies:

• GE Healthcare Dependency: GE Healthcare accounts for 17% of revenues. A distribution agreement for Hoefer products expires in September 2008; failure to renew on favorable terms could materially impact revenue.
• Divestiture Uncertainty: The company continues to seek a buyer for the remaining Capital Equipment segment (COPAS line). Failure to sell could result in further impairment charges or a default under the credit facility if lender consent is not obtained.
• Foreign Exchange: Approximately 58% of revenues are from non-U.S. operations. Currency fluctuations significantly impact reported results (2007 saw a net positive impact of $0.5 million).
• Capital Requirements: While current resources are sufficient for 12+ months, further acquisitions may require additional equity or debt financing.

Investor Verification Checklist

• GE Healthcare Contract Status: Verify the terms and status of the new distribution agreement with GE Healthcare, given the September 2008 expiration of the current Hoefer agreement.
• Discontinued Operations Sale: Monitor progress on the sale of the remaining COPAS flow cytometry product line and potential for further impairment charges if the sale is delayed.
• Debt Covenants: Confirm continued compliance with the $20 million credit facility covenants, particularly regarding the sale of the remaining Capital Equipment segment.
• Integration of Panlab: Assess the profitability trajectory of the Panlab acquisition and its impact on overall gross margins.
• Stock Repurchase Program: Note the authorization of a $10 million stock repurchase program (no shares repurchased as of Dec 31, 2007) and monitor future activity.